Related references
Note: Only part of the references are listed.Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)
Alexander M. Menzies et al.
NATURE MEDICINE (2021)
Paradigms on Immunotherapy Combinations with Chemotherapy
Diego Salas-Benito et al.
CANCER DISCOVERY (2021)
Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort
Xue Bai et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Considerations for treatment duration in responders to immune checkpoint inhibitors
Thomas U. Marron et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Effects of Chemotherapy Agents on Circulating Leukocyte Populations: Potential Implications for the Success of CAR-T Cell Therapies
Nga T. H. Truong et al.
CANCERS (2021)
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Yelena Y. Janjigian et al.
LANCET (2021)
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
Thomas Powles et al.
NATURE (2021)
From Immunogenic Cell Death to Immunogenic Modulation: Select Chemotherapy Regimens Induce a Spectrum of Immune-Enhancing Activities in the Tumor Microenvironment
Kellsye P. Fabian et al.
FRONTIERS IN ONCOLOGY (2021)
Neoadjuvant checkpoint blockade for cancer immunotherapy
Suzanne L. Topalian et al.
SCIENCE (2020)
Acquired Resistance to Immune Checkpoint Inhibitors
Adam J. Schoenfeld et al.
CANCER CELL (2020)
The Role of Antigen Spreading in the Efficacy of Immunotherapies
Peter Brossart
CLINICAL CANCER RESEARCH (2020)
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce
Harriet M. Kluger et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Immunotherapy discontinuation - how, and when? Data from melanoma as a paradigm
Caroline Robert et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Lingering effects of chemotherapy on mature T cells impair proliferation
Rajat K. Das et al.
BLOOD ADVANCES (2020)
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Javier Cortes et al.
LANCET (2020)
Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab
Guillaume Herbreteau et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy
Laura Boyero et al.
CANCERS (2020)
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death (vol 8, e000337, 2020)
Lorenzo Galluzzi et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Role of membrane-embedded drug efflux ABC transporters in the cancer chemotherapy
Sonu Kumar Gupta et al.
ONCOLOGY REVIEWS (2020)
Tumour-intrinsic resistance to immune checkpoint blockade
Anusha Kalbasi et al.
NATURE REVIEWS IMMUNOLOGY (2020)
The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment
Jake S. O'Donnell et al.
CLINICAL CANCER RESEARCH (2019)
Delayed immune-related events (DIRE) after discontinuation of immunotherapy: updates diagnostic hazard of autoimmunity at a distance
Marcus A. Couey et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
125OPembrolizumab + chemotherapy for advanced G/GEJ adenocarcinoma (GC): The phase III KEYNOTE-062 study
H C Chung et al.
ANNALS OF ONCOLOGY (2019)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness et al.
LANCET (2019)
Cancer immunoediting and resistance to T cell-based immunotherapy
Jake S. O'Donnell et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Tumour heterogeneity and resistance to cancer therapies
Ibiayi Dagogo-Jack et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer
Timothy O'Donnell et al.
BMC CANCER (2018)
Pseudoprogression and hyperprogression after checkpoint blockade
Qiaohong Wang et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy
Amber J. Giles et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA
K. G. Paulson et al.
NATURE COMMUNICATIONS (2018)
Harness the synergy between targeted therapy and immunotherapy: what have we learned and where are we headed?
Xiaoyan Liu et al.
ONCOTARGET (2017)
Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy
Adam C. Palmer et al.
CELL (2017)
The Different Mechanisms of Cancer Drug Resistance: A Brief Review
Behzad Mansoori et al.
ADVANCED PHARMACEUTICAL BULLETIN (2017)
Transcriptional Mechanisms of Resistance to Anti-PD-1 Therapy
Maria L. Ascierto et al.
CLINICAL CANCER RESEARCH (2017)
Intrinsic Resistance of Solid Tumors to Immune Checkpoint Blockade Therapy
Xianda Zhao et al.
CANCER RESEARCH (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
RECIST 1.1-Update and clarification: From the RECIST committee
Lawrence H. Schwartz et al.
EUROPEAN JOURNAL OF CANCER (2016)
Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted Therapy
Sangeetha M. Reddy et al.
CURRENT ONCOLOGY REPORTS (2016)
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
Shohei Koyama et al.
NATURE COMMUNICATIONS (2016)
Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer
Rashmi Verma et al.
BREAST CANCER RESEARCH (2016)
Pseudoprogression and Immune-Related Response in Solid Tumors
Victoria L. Chiou et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy
Jennifer A. Wargo et al.
SEMINARS IN ONCOLOGY (2015)
The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
Leisha A. Emens et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Molecular mechanisms of ATP secretion during immunogenic cell death
I. Martins et al.
CELL DEATH AND DIFFERENTIATION (2014)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Immunological aspects of cancer chemotherapy
Laurence Zitvogel et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
Lionel Apetoh et al.
NATURE MEDICINE (2007)
Share Paper
